Zydus Lifesciences Launches Gates-Backed Combo Vaccine Project for Typhoid and Shigellosis

Zydus Lifesciences Ltd has announced a groundbreaking project to develop a combination vaccine protecting against both typhoid and shigellosis, particularly targeting infants and children. The initiative, supported by the Bill & Melinda Gates Foundation, is set to commence in March 2025. This innovative TCV-Shigella combination vaccine aims to safeguard children under 5 years from shigellosis, a severe diarrheal disease, while also providing protection against typhoid fever. The project builds on Zydus's existing expertise with their ZyVac TCV vaccine, which received WHO prequalification in 2024 for use in children as young as 6 months old.

 

Sources: Zydus Lifesciences Ltd press release, NSE, BSE